Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks; K. M. Kerr; J. Menis; T. S. Mok; U. Nestle; A. Passaro; S. Peters; D. Planchard; E. F. Smit; B. J. Solomon; G. Veronesi; M. Reck; ESMO Guidelines Committee; ESMO  Guidelines Committee

doi:10.1016/j.annonc.2022.12.009

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks^*
, K. M. Kerr
, J. Menis
, T. S. Mok
, U. Nestle
, A. Passaro
, S. Peters
, D. Planchard
, E. F. Smit
, B. J. Solomon
, G. Veronesi
, M. Reck
, ESMO Guidelines Committee
, ESMO Guidelines Committee^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

230 Downloads (Pure)

Original language	English
Pages (from-to)	339-357
Number of pages	19
Journal	Annals of Oncology
Volume	34
Issue number	4
Early online date	1 Apr 2023
DOIs	https://doi.org/10.1016/j.annonc.2022.12.009
Publication status	Published - 1 Apr 2023

Keywords

ESCAT
ESMO Clinical Practice Guideline (CPG)
ESMO-MCBS
oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)
treatment
targeted therapy
TYROSINE KINASE INHIBITORS
PROGRESSION-FREE SURVIVAL
RESPONSE EVALUATION CRITERIA
FACTOR RECEPTOR MUTATIONS
OPEN-LABEL
1ST-LINE TREATMENT
SINGLE-ARM
TREATMENT-NAIVE
EGFR MUTATIONS
ADVANCED NSCLC

Access to Document

10.1016/j.annonc.2022.12.009

Full TextFinal published version, 1.77 MBLicence: Taverne

Cite this

Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., ESMO Guidelines Committee, & Guidelines Committee, ESMO. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 339-357. https://doi.org/10.1016/j.annonc.2022.12.009

@article{a6c20759e209411fb9b7789fc32e2f64,

title = "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up",

keywords = "ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC",

author = "Hendriks, \{L. E.\} and Kerr, \{K. M.\} and J. Menis and Mok, \{T. S.\} and U. Nestle and A. Passaro and S. Peters and D. Planchard and Smit, \{E. F.\} and Solomon, \{B. J.\} and G. Veronesi and M. Reck and \{ESMO Guidelines Committee\} and \{Guidelines Committee\}, ESMO",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.12.009",

language = "English",

volume = "34",

pages = "339--357",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "4",

}

Hendriks, LE, Kerr, KM, Menis, J, Mok, TS, Nestle, U, Passaro, A, Peters, S, Planchard, D, Smit, EF, Solomon, BJ, Veronesi, G, Reck, M, ESMO Guidelines Committee & Guidelines Committee, ESMO 2023, 'Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up', Annals of Oncology, vol. 34, no. 4, pp. 339-357. https://doi.org/10.1016/j.annonc.2022.12.009

TY - JOUR

T1 - Oncogene-addicted metastatic non-small-cell lung cancer

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

AU - Hendriks, L. E.

AU - Kerr, K. M.

AU - Menis, J.

AU - Mok, T. S.

AU - Nestle, U.

AU - Passaro, A.

AU - Peters, S.

AU - Planchard, D.

AU - Smit, E. F.

AU - Solomon, B. J.

AU - Veronesi, G.

AU - Reck, M.

AU - ESMO Guidelines Committee

AU - Guidelines Committee, ESMO

PY - 2023/4/1

Y1 - 2023/4/1

KW - ESCAT

KW - ESMO Clinical Practice Guideline (CPG)

KW - ESMO-MCBS

KW - oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)

KW - treatment

KW - targeted therapy

KW - TYROSINE KINASE INHIBITORS

KW - PROGRESSION-FREE SURVIVAL

KW - RESPONSE EVALUATION CRITERIA

KW - FACTOR RECEPTOR MUTATIONS

KW - OPEN-LABEL

KW - 1ST-LINE TREATMENT

KW - SINGLE-ARM

KW - TREATMENT-NAIVE

KW - EGFR MUTATIONS

KW - ADVANCED NSCLC

U2 - 10.1016/j.annonc.2022.12.009

DO - 10.1016/j.annonc.2022.12.009

M3 - Article

C2 - 36872130

SN - 0923-7534

VL - 34

SP - 339

EP - 357

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -